Pakistan
Tuberculosis profile
| High TB burden | High MDR-TB burden |
Population  2013 182 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 49 (12–110) 27 (6.4–63)
Mortality (HIV+TB only) 0.97 (0.56–1.5) 0.53 (0.31–0.82)
Prevalence  (includes HIV+TB) 620 (520–740) 342 (284–406)
Incidence  (includes HIV+TB) 500 (370–650) 275 (205–357)
Incidence (HIV+TB only) 2.6 (1.2–3.4) 1.4 (0.64–1.9)
Case detection, all forms (%) 58 (44–78)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 4.3 (2.8–5.7) 19 (14–25)
MDR-TB cases among notified pulmonary
TB cases
9 900 (6 400–13 000) 3 100 (2 200–4 000)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 111 682   6 303
Pulmonary, clinically diagnosed 118 279   0
Extrapulmonary 52 646   0
       
Total new and relapse 288 910    
Previously treated, excluding relapses 9 536    
Total cases notified 298 446    
Among 282 607 new cases:
28 113 (10%) cases aged under 15 years; male:female ratio: 1.0
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 5 161 (5%) 3 510 (22%) 12 777
Laboratory-confirmed RR-/MDR-TB cases     2 596
Patients started on MDR-TB treatment     1 495
TB/HIV 2013 Number (%)
TB patients with known HIV status 8 306 (3)
HIV-positive TB patients 36 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New cases registered in 2012 91
Previously treated cases registered in 2012 81
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 70
XDR-TB cases started on second-line treatment in 2011 43
Laboratories 2013  
Smear (per 100 000 population) 0.8
Culture (per 5 million population) 0.3
Drug susceptibility testing (per 5 million population) 0.2
Sites performing Xpert MTB/RIF 32
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 114
% Funded domestically 0%
% Funded internationally 30%
% Unfunded 70%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-03-31 Data: www.who.int/tb/data